About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Therapeutic Advances in Gastroenterology
›
Top Articles
Therapeutic Advances in Gastroenterology
4.7
(top 3%)
Impact Factor
5.2
(top 3%)
extended IF
62
(top 6%)
H-Index
776
authors
902
papers
16.4K
citations
2.9K
citing journals
15.3K
citing authors
Most Cited Articles of Therapeutic Advances in Gastroenterology
Title
Year
Citations
Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation
2013
485
Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ
2013
457
Diagnosis and management of iron deficiency anemia in the 21st century
2011
198
Pancreatic cancer: why is it so hard to treat?
2013
193
Overutilization of proton-pump inhibitors: what the clinician needs to know
2012
191
Fecal microbiota transplantation: in perspective
2016
186
Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders
2012
173
Current status of novel antifibrotic therapies in patients with chronic liver disease
2011
148
Use of probiotics in gastrointestinal disorders: what to recommend?
2010
146
Secondary causes of nonalcoholic fatty liver disease
2012
139
The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?
2013
137
Fecal microbiota transplantation in relapsing Clostridium difficile infection
2012
134
Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection
2011
118
The emerging role of miRNAs in inflammatory bowel disease: a review
2015
111
Immunogenicity of biologics in inflammatory bowel disease
2018
110
The role and utility of faecal markers in inflammatory bowel disease
2015
109
The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial
2009
107
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions
2016
104
Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?
2012
103
Treatment options for nonalcoholic fatty liver disease
2010
103
Treatment of alcoholic liver disease
2011
101
Managing bile acid diarrhoea
2010
99
A randomized trial of a fully covered self-expandable metallic stent versus plastic stents in anastomotic biliary strictures after liver transplantation
2014
95
Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease?
2013
95
The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy
2012
95
previous
2016
2017
2018
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.